Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct 1;9(10):882-891.
doi: 10.1001/jamacardio.2024.2298.

Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial

Jasmine Melissa Madsen  1 , Thomas Engstrøm  1   2 , Laust Emil Roelsgaard Obling  1 , Yan Zhou  1 , Lars Nepper-Christensen  1 , Rasmus Paulin Beske  1 , Niels Grove Vejlstrup  1 , Lia Evi Bang  1 , Christian Hassager  1   2 , Fredrik Folke  2   3   4 , Kasper Kyhl  1 , Lars Bredevang Andersen  5 , Helle Collatz Christensen  2   5 , Laura Rytoft  1 , Ketina Arslani  1 , Lene Holmvang  1   2 , Frants Pedersen  1 , Ole Ahlehoff  1 , Reza Jabbari  1 , Charlotte Barfod  3 , Mikkel Hougaard  1 , Mikko Minkkinen  1 , Hans-Henrik Tilsted  1 , Rikke Sørensen  1   2 , Jacob Thomsen Lønborg  1   2
Affiliations
Randomized Controlled Trial

Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial

Jasmine Melissa Madsen et al. JAMA Cardiol. .

Abstract

Importance: In patients with ST-segment elevation myocardial infarction (STEMI), acute inflammation is related to the extent of myocardial damage and may increase infarct size. Thus, administration of pulse-dose glucocorticoid in the very early phase of infarction may reduce infarct size.

Objective: To determine the cardioprotective effect of prehospital pulse-dose glucocorticoid in patients with STEMI.

Design, setting, and participants: This was a 1:1 investigator-initiated, blinded, placebo-controlled, randomized clinical trial conducted between November 14, 2022, and October 17, 2023, with last follow-up on January 17, 2024. Patients 18 years and older with less than 12 hours of acute chest pain and STEMI were included in the prehospital setting throughout the Region Zealand and Capital Region of Denmark and transferred to Rigshospitalet, Denmark.

Intervention: Patients were randomly allocated to intravenous glucocorticoid (methylprednisolone, 250 mg) or placebo in the prehospital setting.

Main outcomes and measures: The primary outcome was final infarct size on cardiac magnetic resonance (CMR) at 3 months. The power calculation was based on an anticipated final infarct size of 13%. Secondary outcomes included CMR outcomes on acute scan and at 3 months, peak of cardiac biomarkers, clinical end points at 3 months, and adverse events.

Results: Of 530 included patients (median [IQR] age, 65 [56-75] years; 418 male [78.9%]) with STEMI, 401 (76%) were assessed for the primary outcome, with 198 patients treated with glucocorticoid and 203 with placebo. Median final infarct size was similar in the treatment groups (glucocorticoid, 5%; IQR, 2%-11% vs placebo, 6%; IQR, 2%-13%; P = .24). Compared with placebo, the glucocorticoid group had smaller acute infarct size (odds ratio, 0.78; 95% CI, 0.61-1.00), less microvascular obstruction (relative risk ratio, 0.83; 95% CI, 0.71-0.99), and greater acute left ventricular ejection fraction (mean difference, 4.44%; 95% CI, 2.01%-6.87%). Other secondary outcomes were similar in both groups.

Conclusions and relevance: In patients with STEMI, treatment with prehospital pulse-dose glucocorticoid did not reduce final infarct size after 3 months. However, the trial was likely underpowered as the final infarct size was smaller than anticipated. The glucocorticoid group had improved acute parameters compared with placebo.

Trial registration: ClinicalTrials.gov Identifier: NCT05462730.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Madsen reported receiving grants from the Research Foundation of Rigshospitalet during the conduct of the study. Dr Engstrøm reported receiving speaker and/or advisory board fees from Abbott, Boston Scientific, and Novo Nordisk outside the submitted work. Dr Beske reported receiving grants from the Novo Nordisk Foundation during the conduct of the study. Dr Arslani reported receiving grants from the Swiss National Science Foundation (P500PM_202963), the Swiss Academy of Medical Sciences, and the Gottfried and Julia Bangerter-Rhyner-Foundation outside the submitted work. Dr Holmvang reported receiving travel grants from Abbott and Boston Scientific outside the submitted work. Dr Minkkinen reported receiving personal fees from Boston Scientific and Abbott outside the submitted work. Dr Sørensen reported receiving lecture fees and grants from AstraZeneca, Pfizer, Novo Nordisk Foundation, and Gangstedfonden outside the submitted work. Dr Lønborg reported receiving speakers fees from Boston Scientific and Abbott and grants from Boston Scientific outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Study Flowchart
Shown is the study flowchart including postrandomization exclusions and the reasons hereof. The modified intention-to-treat population included all patients who fulfilled all eligibility criteria. Logistics refers to patients not being able to be transported to Rigshospitalet, Denmark, other refers to reasons such as poor hearing, chronic pain, or other reasons for not being able to complete a cardiac magnetic resonance imaging scan, primary outcome not evaluable refers to poor image quality and the readers have not been able to analysis the images for the primary outcome. SCAD indicates spontaneous coronary artery dissection; STEMI, ST-segment elevation myocardial infarction.
Figure 2.
Figure 2.. Box Plots Illustrating Infarct Size in the Modified Intention-to-Treat Population
Shown are box plots of acute and final infarct size stratified by treatment group in the modified intention-to-treat population. A, Final infarct size (primary outcome). B, Acute infarct size (secondary outcome). Infarct size is reported as a percentage of the left ventricle. Acute refers to values on the acute cardiac magnetic resonance scan. Final refers to values on the follow-up cardiac magnetic resonance scan. The lower and upper hinges correspond to the first and third quartiles (the 25th and 75th percentiles). The upper whisker extends from the hinge to the largest value no further than 1.5 × IQR from the hinge (where IQR is the distance between the first and third quartiles). The lower whisker extends from the hinge to the smallest value at most 1.5 × IQR of the hinge. Data beyond the end of the whiskers are called outlying points and are plotted individually.
Figure 3.
Figure 3.. Subgroup Analysis of the Primary Outcome: Wilcoxon-Mann-Whitney Odds Ratio (OR)
Shown is the subgroup analysis of median final infarct size at 3 months in each group and Wilcoxon-Mann-Whitney OR with 95% CI in the glucocorticoid group and placebo group. The widths of the CIs were not adjusted for multiple comparisons, and the reported CIs should not be used for hypothesis testing. CABG indicates coronary artery bypass graft; LAD, left anterior descending artery; LM, left main artery; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction. aMissing: time from symptom onset to first wire, 10 in the placebo group and 7 in the glucocorticoid group. bMissing: time from study intervention to first wire, 10 in the placebo group and 7 in the glucocorticoid group. cMissing: time from first medical contact to first wire, 10 in the placebo group and 7 in the glucocorticoid group.
See this image and copyright information in PMC

References

    1. Thrane PG, Olesen KKW, Thim T, et al. Mortality trends after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2023;82(10):999-1010. doi: 10.1016/j.jacc.2023.06.025 - DOI - PubMed
    1. Desta L, Jernberg T, Löfman I, et al. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction: the SWEDEHEART registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies), a study of 199 851 patients admitted with index acute myocardial infarctions, 1996 to 2008. JACC Heart Fail. 2015;3(3):234-242. doi: 10.1016/j.jchf.2014.10.007 - DOI - PubMed
    1. Vogel B, Claessen BE, Arnold SV, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers. 2019;5(1):39. doi: 10.1038/s41572-019-0090-3 - DOI - PubMed
    1. Lønborg J, Vejlstrup N, Kelbæk H, et al. Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. Eur Heart J Cardiovasc Imaging. 2013;14(4):387-395. doi: 10.1093/ehjci/jes271 - DOI - PubMed
    1. Westman PC, Lipinski MJ, Luger D, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2016;67(17):2050-2060. doi: 10.1016/j.jacc.2016.01.073 - DOI - PubMed

Publication types

Associated data